Wall Street expects a year-over-year increase in earnings on higher revenues when Myriad Genetics (MYGN) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock ma ...

精神健康问题影响 - 美国有44%的人因精神健康问题感到失去了生活中的时间[1] - 一半被诊断为焦虑和/或抑郁的人表示，由于精神健康问题，他们失去了自己生命中的年华[2] - 有71%的受访者表示，精神健康问题让他们无法全神贯注参加重要活动[3] - 超过半数被诊断为焦虑和/或抑郁的人表示，精神健康问题导致他们错过了重要的人生事件[4]

SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that Prenatal Diagnosis has published a study1 demonstrating exceptional positive predictive value (PPV) for 22q11.2 microdeletion screening using Myriad's prenatal cell-free DNA (pcfDNA) screen, Prequel®, which incorporates fetal fraction amplification. Prior studies from other commercial pcfDNA laboratories have reported a broad range of PPV for the 2 ...

Myriad Genetics, Inc. (MYGN) recently announced results from a multi-year, real-world study that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight Psychotropic test. The study consisted of nearly 21,000 patients.Management expects to share additional study results later in 2024.The study’s latest positive initial outcome is a significant stepping stone for Myriad Genetics and is likely to boost the usage of its GeneSight Psychotropic test, part of i ...

Myriad Genetics (MYGN) is well poised for growth in the coming quarters, backed by strong improvement in testing volume across all its businesses. Strong solvency is an added advantage. Yet, foreign exchange headwinds and stiff competition are a concern.In the past six months, this Zacks Rank #3 (Hold) stock has gained 32.8% compared with a 0.6% rise of the industry and a 20% rise of the S&P 500 composite.The renowned genetic testing and precision medicine company has a market capitalization of $1.83 billio ...

SALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight® Psychotropic test. "We are encouraged by the initial results of this study that showed how the proportion of patients with hospitalizations was significantly reduced after GeneSi ...

SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.  U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad's foundational and proprietary method of preparing cell free DNA. This method ...

SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that the U.S. Patent and Trademark Office has granted a patent that covers the use of push-button blood collection devices for PCR-based fetal sex determination. U.S. Patent No. 11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm, provides protection for Myriad's SneakPeek Snap® products in the U.S through 2040. The patent fu ...

Myriad Genetics, Inc. (MYGN) reported an adjusted earnings per share (EPS) of 4 cents per share in the fourth quarter of 2023 versus the year-ago quarter’s loss of 12 cents. The metric surpassed the Zacks Consensus Estimate of 2 cents by 100%.The quarter’s adjustments exclude amortization expenses from acquired intangible assets, equity compensations and real estate optimization.The GAAP loss was 36 cents compared with the prior-year quarter’s loss of 52 cents.For the full year, the adjusted loss was 27 cen ...

财务数据和关键指标变化 - 2023年全年收入同比增长超过11% [15] - 2023年第四季度实现正的经调整每股收益和正的经调整经营现金流 [15] - 2024年全年收入指引上调,并引入正的经调整每股收益指引 [16] - 2023年初因转换GeneSight的PLA编码和多家蓝十字蓝盾健康计划的转换,导致ASP压缩超过公司预期的3%-5%范围 [19][20] - 2024年ASP压缩预计将在3%-5%的目标范围内 [20] 各条业务线数据和关键指标变化 - 2023年遗传性癌症、产前和药理基因组学业务均实现两位数增长 [25] - 2023年第四季度GeneSight业务量同比增长21%,收入同比增长11% [27] - 2023年第四季度遗传性癌症业务量同比增长10%,不含SneakPeek的产前业务量同比增长17% [29] - 2023年第四季度泌尿肿瘤业务Prolaris收入同比增长14%,全年增长21% [30] 各个市场数据和关键指标变化 - 行业内前20大公司集中度不到20%,公司有很大的市场份额提升空间 [17] - 公司正在与更多医疗系统建立合作关系,打开了此前被拒之门外的学术医疗中心市场 [94][173] 公司战略和发展方向及行业竞争 - 公司正在通过技术和医疗系统合作,提升产品的临床效用和易用性,扩大采用和获取 [13][14] - 公司收购Intermountain Precision Genomics,将精准肿瘤和精准液体检测能力纳入,实现对全部经济收益的掌控 [18] - 公司未来几年将推出Foresight Universal Plus、FirstGene、Precise Liquid和Precise MRD等新产品 [22][33] - 公司正在加强数字化技术应用,提升客户体验,如EMR集成、患者门户等 [47][48] 管理层对经营环境和未来前景的评论 - 基因组检测和精准医疗的应用场景正在扩大,为公司的有机增长提供强劲动力 [17] - 公司正在持续提升实验室运营和商业引擎的效率,为2024年及以后的加速盈利增长奠定基础 [19][58][59] - 公司未来几年将受益于近三年的研发投入,临床证据的积累将支持指南扩展、临床效用和报销的改善 [21] 问答环节重要的提问和回答 问题1 **关于MRD的进展** **提问内容** 公司MRD的时间线和报销路径如何? [74][75] **回答内容** 公司正在与Memorial Sloan Kettering、MD Anderson等机构开展MRD临床研究,预计2025年实现商业化发布。公司有信心在专利和自主研发的基础上推出高灵敏度的MRD检测产品,并正在与监管机构和支付方就报销路径进行沟通。[75][76][160] 问题2 **关于遗传性癌症业务的ASP** **提问内容** 遗传性癌症业务的ASP趋势如何,是否会受到市场竞争加剧的影响? [86][87][88] **回答内容** 公司不会为了获取市场份额而采取降价策略,而是专注于提供临床差异化的产品。公司已经与多家主要支付方签订了长期合同,对ASP有较好的可见性。未来几年,随着指南扩展、报销政策改善,公司遗传性癌症业务的ASP有望进一步提升。[88][89][90][91] 问题3 **关于实验室自动化带来的成本优化** **提问内容** 实验室自动化和新设施建设对2024年及以后的毛利率有何影响? [173][174][175] **回答内容** 公司正在分阶段完成实验室搬迁和自动化升级,预计到2025年将带来约1200万美元的成本优化。这些投资将逐步体现在毛利率的改善,但具体时间节点还需要视认证、验证等进度而定。公司会继续努力加快这些举措的实施进度,以期在2024年就能部分体现成本优化效果。[173][174][175]